Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
News|Articles|July 8, 2026
First Half 2026 Recap: Nephrology
Author(s)Alex Hillenbrand
Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.
Advertisement
Advertisement
The first half of 2026 marked a transformative period in nephrology, with landmark regulatory approvals, evolving clinical practice guidelines, and pivotal phase 3 trial results accelerating a shift toward precision medicine and disease modification. Across
Related to this article
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Advertisement
Advertisement